Clinical utility of anti‐cytosolic 5’‐nucleotidase 1A antibody in idiopathic inflammatory myopathies

Autor: Leo H. Wang, Namita Goyal, Alan Pestronk, Jonathan Cauchi, Conrad C. Weihl, Yessar Hussain, Sarah Robinson, Chiseko Ikenaga, Joshua C. Kershen, Michael Wallendorf, Robert C. Bucelli, Andrew R. Findlay, Tahseen Mozaffar, Brent A. Beson
Rok vydání: 2021
Předmět:
Adult
Male
0301 basic medicine
medicine.medical_specialty
Clinical Sciences
Neurosciences. Biological psychiatry. Neuropsychiatry
Antisynthetase syndrome
Malignancy
Autoimmune Disease
Gastroenterology
Inclusion Body
Myositis
Inclusion Body
5'-nucleotidase
03 medical and health sciences
Rare Diseases
0302 clinical medicine
Clinical Research
Internal medicine
medicine
Humans
RC346-429
5'-Nucleotidase
Research Articles
Myositis
Autoantibodies
Retrospective Studies
Aged
biology
business.industry
Inflammatory and immune system
General Neuroscience
Neurosciences
Interstitial lung disease
Middle Aged
Dermatomyositis
medicine.disease
030104 developmental biology
biology.protein
Female
Neurology. Diseases of the nervous system
Neurology (clinical)
Antibody
Inclusion body myositis
business
030217 neurology & neurosurgery
Research Article
RC321-571
Zdroj: Annals of Clinical and Translational Neurology, Vol 8, Iss 3, Pp 571-578 (2021)
Annals of clinical and translational neurology, vol 8, iss 3
Annals of Clinical and Translational Neurology
ISSN: 2328-9503
DOI: 10.1002/acn3.51294
Popis: Author(s): Ikenaga, Chiseko; Findlay, Andrew R; Goyal, Namita A; Robinson, Sarah; Cauchi, Jonathan; Hussain, Yessar; Wang, Leo H; Kershen, Joshua C; Beson, Brent A; Wallendorf, Michael; Bucelli, Robert C; Mozaffar, Tahseen; Pestronk, Alan; Weihl, Conrad C | Abstract: ObjectiveTo define the clinicopathologic features and diagnostic utility associated with anti-cytosolic 5'-nucleotidase 1A (NT5C1A) antibody seropositivity in idiopathic inflammatory myopathies (IIMs).MethodsAnti-NT5C1A antibody status was clinically tested between 2014 and 2019 in the Washington University neuromuscular clinical laboratory. Using clinicopathologic information available for 593 patients, we classified them as inclusion body myositis (IBM), dermatomyositis, antisynthetase syndrome, immune-mediated necrotizing myopathy (IMNM), nonspecific myositis, or noninflammatory muscle diseases.ResultsOf 593 patients, anti-NT5C1A antibody was found in 159/249 (64%) IBM, 11/53 (21%) dermatomyositis, 7/27 (26%) antisynthetase syndrome, 9/76 (12%) IMNM, 20/84 (24%) nonspecific myositis, and 6/104 (6%) noninflammatory muscle diseases patients. Among patients with IBM, anti-NT5C1A antibody seropositive patients had more cytochrome oxidase-negative fibers compared with anti-NT5C1A antibody seronegative patients. Among 14 IBM patients initially negative for anti-NT5C1A antibody, three patients (21%) converted to positive. Anti-NT5C1A antibody seropositivity did not correlate with malignancy, interstitial lung disease, response to treatments in dermatomyositis, antisynthetase syndrome, and IMNM, or survival in IIMs.InterpretationAnti-NT5C1A antibody is associated with IBM. However, the seropositivity can also be seen in non-IBM IIMs and it does not correlate with any prognostic factors or survival.
Databáze: OpenAIRE
Externí odkaz: